Supplementary Materials and Methods

Immunohistochemistry
Immunostaining was done with monoclonal antibodies directed against mucin 1 (clone MA695; dilution 1:100), mucin 2 (clone Ccp58; both Novocastra, Leica Microsystems GmbH, Wetzlar, Germany; 1:100), mucin 5 (clone 45M1; Thermo Scientific, Schwerte, Germany; 1:100), mucin 6 (clone CLH5; 1:100), CD10 (clone 56C6; both Novocastra; 1:10), E-cadherin (clone SPM471; ZYTOMED Systems GmbH, Berlin, Germany; 1:400), -catenin (clone Cat-5H10; Life Technologies GmbH, Darmstadt, Germany; 1:300), and a polyclonal antibody directed against lysozyme (1:3000; DAKO, Glostrup, Denmark).
Antigen retrieval was done with ER1 (citrate buffer Bond pH 6.0; mucin 1, CD10) or ER2 (EDTA-buffer Bond pH 8.9; mucin 2, mucin 6, E-cadherin, -catenin) both Novocastra). Epstein-Barr-Virus encoded RNA was detected using the EBERprobe (Novocastra) and the Bond Refine Detection system according to the manufacturer´s instructions (Leica Microsystems GmbH).
Evaluation of Immunostaining
Immunostaining of the TMAs was evaluated by applying an immunoreactivity scoring system (IRS). Briefly, category A documented the intensity of immunostaining as 0 (no immunostaining), 1 (weak), 2 (moderate), and 3 (strong). Category B documented the percentage of immunoreactive cells as 0 (no immunoreactive cells), 
Detection of Helicobacter pylori by Histology and Polymerase Chain Reaction
Infection with H. pylori was evaluated histologically using the modified Giemsastaining and PCR. 4 H. pylori-specific DNA sequences were detected by a PCR-based assay targeting the 16S rRNA gene of H. pylori. 5 In short, a 109 bp fragment of the 16S rRNA gene was amplified with the primers Hp1 (5´-CTGGAGAGACTAAGCCCTCC-3´) and Hp2 (5´-ATTACTGACGCTGATTGTGC-3´) following the PCR parameters described by Chisholm et al. 5 Amplification products were assessed by agarose gel electrophoresis.
